Cannabis & Gulf War Illness (GWI)
Gulf War Illness affects approximately 32% of 1990–91 Gulf War veterans. There is no FDA-approved treatment. Emerging research points to endocannabinoid system dysfunction as one possible mechanism, and a 2026 trial of OEA (an endocannabinoid-related compound, not cannabis itself) showed preliminary benefit — but direct cannabis research is still minimal.
The Honest Summary
Preclinical research finds endocannabinoid deficiency in GWI animal models. The 2026 Kothapalli et al. RCT tested OEA supplementation (not cannabis) in 52 GWI veterans and found improved mood and reduced fatigue. Direct cannabis RCTs for GWI do not yet exist. GWI has no FDA-approved treatment, and cannabis is not a substitute for engaging with VA GWI services.
What Is Gulf War Illness?
Gulf War Illness is a multi-symptom condition affecting approximately 32% of the 697,000 U.S. troops who served in Operation Desert Shield / Desert Storm (1990–1991). It is formally recognized by VA as a compensable condition and includes:
- Chronic fatigue that does not resolve with rest
- Cognitive dysfunction ("Gulf War brain fog")
- Widespread musculoskeletal pain
- Gastrointestinal symptoms
- Headaches
- Sleep disturbance
- Mood disturbance
- Respiratory symptoms
- Skin abnormalities
The etiology is not fully understood, but candidate mechanisms include exposure to sarin and other nerve agent precursors during demolition of Iraqi chemical depots (notably Khamisiyah), pyridostigmine bromide pretreatment, pesticide exposure, burn pit smoke, depleted uranium, and psychological stress. GWI is not psychosomatic, despite years of dismissive framing. It is a real condition with real biological markers.
The Endocannabinoid Hypothesis
Squire et al. 2024 found endocannabinoid deficiency in a GWI mouse model, suggesting that the multi-symptom presentation of GWI may share mechanism with other endocannabinoid deficiency conditions (which some researchers have hypothesized for fibromyalgia, migraine, and irritable bowel syndrome as well). This is preclinical work and should not be over-interpreted, but it provides a plausible biological rationale for why GWI veterans might benefit from treatments that support endocannabinoid signaling.
The 2026 Kothapalli OEA Trial
This first human RCT targeting endocannabinoid pathways in GWI tested oleoylethanolamide (OEA) supplementation in 52 GWI veterans. OEA is an endogenous lipid that binds the PPAR-alpha receptor and is structurally related to anandamide. It is not cannabis and does not act at CB1/CB2 receptors. The trial found improved mood and reduced fatigue compared to placebo.
This is a promising preliminary finding, and it supports the broader hypothesis that endocannabinoid system modulation may help some GWI symptoms. But it does not directly support cannabis use for GWI — OEA works through a different mechanism.
Direct Cannabis Research in GWI
As of April 2026, there are no completed randomized controlled trials of plant cannabis or pharmaceutical cannabinoids specifically in GWI populations. Anecdotal reports from GWI veterans describe benefit for pain, sleep, and mood — consistent with the general cannabis literature in these areas — but the GWI-specific questions remain unstudied.
Chronic Pain Overlap
Many GWI veterans experience widespread musculoskeletal pain, which may respond to cannabis in the same way that general chronic pain does. The NASEM 2017 evidence for chronic pain (see chronic pain page) applies by extension, though with the usual limitations that GWI pain is often more diffuse and multi-system than the neuropathic pain that has the strongest evidence base.
VA Gulf War Services
VA offers the following for Gulf War veterans:
- Gulf War Registry health exam — free, comprehensive health evaluation for all Gulf War-era veterans
- War Related Illness and Injury Study Centers (WRIISC) — specialized centers for complex multi-symptom presentations, located in DC, East Orange NJ, and Palo Alto CA
- Gulf War Research Strategic Plan — ongoing VA-funded research into mechanisms and treatments
- Presumptive service connection — many GWI symptoms are presumptively service-connected under 38 CFR § 3.317
What This Means for GWI Veterans
- Cannabis has no proven benefit for GWI as a whole. Preclinical work is promising; human evidence is minimal.
- For specific GWI symptoms (pain, sleep, mood), general cannabis evidence may apply — with all its limitations.
- OEA is not cannabis. If the 2026 Kothapalli findings interest you, OEA supplements are available as non-cannabis dietary supplements and act through a different mechanism.
- Engage with VA WRIISC or Gulf War services. These are the most experienced clinicians for your condition.
- GWI symptoms and cannabis adverse effects overlap. Fatigue, cognitive symptoms, and mood effects from chronic cannabis use can mimic GWI, making it hard to tell what cannabis is doing.